Should Your Employer Have Access to Your Fitbit Data?

Should Your Employer Have Access to Your Fitbit Data?

A woman using a wearable device to track her fitness activities.

(© olegbreslavtsev/Fotolia)


Keep Reading Keep Reading
Junaid Nabi
Junaid Nabi, MD, MPH, is a physician, public health researcher, and a medical journalist. He currently manages several research projects at Brigham Health that include investigating provider- and hospital-level factors associated with racial and ethnic disparities in surgical oncology; evaluating the fiscal impact of consolidating care of complex patients; and, examining systematic factors that lead to opioid over-prescribing patterns after surgery. He has also undertaken research that examined the effect of health disparities that arise from social and political disenfranchisement and the relationship between trauma care and post-traumatic stress disorder (PTSD). Previously, he was a Fellow in Bioethics at Harvard Medical School Center for Bioethics where he studied bioethical issues in global healthcare delivery; role of bioethicists in Artificial Intelligence, Machine Learning, and other evolving technologies; and, emotional intelligence in bioethical analysis. He is a New Voices Fellow at The Aspen Institute, Washington, D.C., and a Fellow at Harvard Graduate School Leadership Institute, Boston.
Get our top stories twice a month
Follow us on
Patients voice hope and relief as FDA gives third-ever drug approval for ALS

On Sept. 29, the FDA approved Relyvrio, a new drug for ALS, even though a study of 137 ALS patients did not result in “substantial evidence” that Relyvrio was effective.

Adobe Stock

At age 52, Glen Rouse suffered from arm weakness and a lot of muscle twitches. “I first thought something was wrong when I could not throw a 50-pound bag of dog food over the tailgate of my truck—something I use to do effortlessly,” said the 54-year-old resident of Anderson, California, about three hours north of San Francisco.

In August, Rouse retired as a forester for a private timber company, a job he had held for 31 years. The impetus: amyotrophic lateral sclerosis, or ALS, a progressive neuromuscular disease that is commonly known as Lou Gehrig’s disease, named after the New York Yankees’ first baseman who succumbed to it less than a month shy of his 38th birthday in 1941. ALS eventually robs an individual of the ability to talk, walk, chew, swallow and breathe.

Keep Reading Keep Reading
Susan Kreimer
Susan Kreimer is a New York-based freelance journalist who has followed the landscape of health care since the late 1990s, initially as a staff reporter for major daily newspapers. She writes about breakthrough studies, personal health, and the business of clinical practice. Raised in the Chicago area, she holds a B.A. in Journalism/Mass Communication and French from the University of Iowa and an M.S. from the Columbia University Graduate School of Journalism.
Friday Five Podcast: New drug may slow the rate of Alzheimer's disease

On September 27, pharmaceuticals Biogen and Eisai announced that their drug, lecanemab, can slow the rate of Alzheimer's disease, according to a clinical trial. Today's Friday Five episode covers this story and other health research over the month of September.

Adobe Stock

The Friday Five covers important stories in health and science research that you may have missed - usually over the previous week, but today's episode is a lookback on important studies over the month of September.

Most recently, on September 27, pharmaceuticals Biogen and Eisai announced that a clinical trial showed their drug, lecanemab, can slow the rate of Alzheimer's disease. There are plenty of controversies and troubling ethical issues in science – and we get into many of them in our online magazine – but this news roundup focuses on scientific creativity and progress to give you a therapeutic dose of inspiration headed into the weekend and the new month.

Keep Reading Keep Reading
Matt Fuchs

Matt Fuchs is the editor-in-chief of Leaps.org. He is also a contributing reporter to the Washington Post and has written for the New York Times, Time Magazine, WIRED and the Washington Post Magazine, among other outlets. Follow him on Twitter @fuchswriter.